Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Author Correction: Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.

Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, Gutiérrez-Vázquez C, Kenison J, Tjon EC, Barroso A, Vandeventer T, de Lima KA, Rothweiler S, Mayo L, Ghannam S, Zandee S, Healy L, Sherr D, Farez MF, Prat A, Antel J, Reardon DA, Zhang H, Robson SC, Getz G, Weiner HL, Quintana FJ.

Nat Neurosci. 2019 Jun 13. doi: 10.1038/s41593-019-0446-8. [Epub ahead of print]

PMID:
31197266
2.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
3.

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.

Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T.

Cancer Chemother Pharmacol. 2019 Jun 1. doi: 10.1007/s00280-019-03879-2. [Epub ahead of print]

PMID:
31154523
4.

Survival and prognostic factors in surgically treated brain metastases.

Kavouridis VK, Harary M, Hulsbergen AFC, Lo YT, Reardon DA, Aizer AA, Iorgulescu JB, Smith TR.

J Neurooncol. 2019 Jun;143(2):359-367. doi: 10.1007/s11060-019-03171-6. Epub 2019 Apr 16.

PMID:
30989623
5.

Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.

Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, Gutiérrez-Vázquez C, Kenison J, Tjon EC, Barroso A, Vandeventer T, de Lima KA, Rothweiler S, Mayo L, Ghannam S, Zandee S, Healy L, Sherr D, Farez MF, Prat A, Antel J, Reardon DA, Zhang H, Robson SC, Getz G, Weiner HL, Quintana FJ.

Nat Neurosci. 2019 May;22(5):729-740. doi: 10.1038/s41593-019-0370-y. Epub 2019 Apr 8. Erratum in: Nat Neurosci. 2019 Jun 13;:.

PMID:
30962630
6.

Efficacy and safety of immune checkpoint blockade for brain metastases.

Harary M, Reardon DA, Iorgulescu JB.

CNS Oncol. 2019 Mar 11. doi: 10.2217/cns-2018-0018. [Epub ahead of print] No abstract available.

7.

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.

Dunn IF, Du Z, Touat M, Sisti MB, Wen PY, Umeton R, Dubuc AM, Ducar M, Canoll PD, Severson E, Elvin JA, Ramkissoon SH, Lin JR, Cabrera L, Acevedo B, Sorger PK, Ligon KL, Santagata S, Reardon DA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27. No abstract available.

8.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM.

Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.

PMID:
30742122
9.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

10.

The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Iorgulescu JB, Torre M, Harary M, Smith TR, Aizer AA, Reardon DA, Barnholtz-Sloan JS, Perry A.

Clin Cancer Res. 2019 Apr 15;25(8):2656-2663. doi: 10.1158/1078-0432.CCR-18-3101. Epub 2019 Jan 11.

PMID:
30635340
11.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA.

Nature. 2019 Jan;565(7738):234-239. doi: 10.1038/s41586-018-0792-9. Epub 2018 Dec 19.

PMID:
30568305
12.

Pseudoprogression: fact or wishful thinking in neuro-oncology?

Reardon DA, Weller M.

Lancet Oncol. 2018 Dec;19(12):1561-1563. doi: 10.1016/S1470-2045(18)30654-5. No abstract available.

PMID:
30507413
13.

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY.

AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. doi: 10.2214/AJR.18.19988. Epub 2018 Oct 17.

PMID:
30332289
14.

Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.

Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H.

Clin Cancer Res. 2019 Jan 1;25(1):290-299. doi: 10.1158/1078-0432.CCR-18-2311. Epub 2018 Oct 2.

PMID:
30279232
15.

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.

Kurz SC, Cabrera LP, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee EQ, Reardon DA, Wen PY.

Neurology. 2018 Oct 2;91(14):e1355-e1359. doi: 10.1212/WNL.0000000000006283. Epub 2018 Aug 31.

PMID:
30171077
16.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

PMID:
30137421
17.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

18.

Immunotherapy for glioblastoma: going viral.

Iorgulescu JB, Reardon DA, Chiocca EA, Wu CJ.

Nat Med. 2018 Aug;24(8):1094-1096. doi: 10.1038/s41591-018-0142-3. No abstract available.

19.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Sep;101:95-104. doi: 10.1016/j.ejca.2018.06.029. Epub 2018 Jul 20.

PMID:
30036741
20.

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.

Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR.

Cancer Immunol Res. 2018 Sep;6(9):1039-1045. doi: 10.1158/2326-6066.CIR-18-0067. Epub 2018 Jul 12.

PMID:
30002157
21.

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM.

Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.

22.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

23.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

PMID:
29941486
24.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

25.

Bevacizumab biosimilars: scientific justification for extrapolation of indications.

Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I.

Future Oncol. 2018 Oct;14(24):2507-2520. doi: 10.2217/fon-2018-0051. Epub 2018 Apr 25. Review.

26.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Sep 3;20(10):1411-1418. doi: 10.1093/neuonc/noy054.

27.

Concepts for Immunotherapies in Gliomas.

Platten M, Reardon DA.

Semin Neurol. 2018 Feb;38(1):62-72. doi: 10.1055/s-0037-1620274. Epub 2018 Mar 16. Review.

PMID:
29548053
28.

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA.

Clin Cancer Res. 2018 Jun 1;24(11):2574-2584. doi: 10.1158/1078-0432.CCR-17-2954. Epub 2018 Mar 6.

29.

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, Foreman NK, Manley PE, Kieran MW, Reardon DA, Sorger PK, Santagata S.

Neuro Oncol. 2018 Jul 5;20(8):1101-1112. doi: 10.1093/neuonc/noy035.

PMID:
29509940
30.

Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.

Zhou M, Zhou Y, Liao H, Rowland BC, Kong X, Arvold ND, Reardon DA, Wen PY, Lin AP, Huang RY.

Neuro Oncol. 2018 Aug 2;20(9):1262-1271. doi: 10.1093/neuonc/noy022.

PMID:
29438510
31.

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hicking C, Picard M, Stupp R, Weller M; EORTC Brain Tumor Group and on behalf of the CENTRIC and CORE Clinical Trial Groups.

J Neurooncol. 2018 May;138(1):163-171. doi: 10.1007/s11060-018-2786-8. Epub 2018 Feb 8.

PMID:
29423540
32.

Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.

Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA.

Sci Rep. 2018 Jan 9;8(1):208. doi: 10.1038/s41598-017-18540-2.

33.

Immunotherapy for glioblastoma: on the sidelines or in the game?

Reardon DA, Wucherpfennig K, Chiocca EA.

Discov Med. 2017 Nov;24(133):201-208. Review.

34.

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY.

Cancer. 2018 Apr 1;124(7):1438-1448. doi: 10.1002/cncr.31172. Epub 2017 Dec 19.

35.

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Peters KB, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Desjardins A, Reardon DA, Friedman HS.

J Neurooncol. 2018 Apr;137(2):349-356. doi: 10.1007/s11060-017-2724-1. Epub 2017 Dec 21.

PMID:
29264836
36.

High-grade Gliomas.

Nayak L, Reardon DA.

Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1548-1563. doi: 10.1212/CON.0000000000000554. Review.

PMID:
29200110
37.

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH.

Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208.

38.

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P.

Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202.

39.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

40.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):259-267. doi: 10.1093/neuonc/nox151.

41.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.

Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154.

42.

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.

Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen PY, Chiocca EA, Lawler SE.

Neuro Oncol. 2018 Jan 22;20(2):225-235. doi: 10.1093/neuonc/nox139.

43.

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.

Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.

J Neurooncol. 2017 Dec;135(3):581-591. doi: 10.1007/s11060-017-2611-9. Epub 2017 Oct 3.

PMID:
28975467
44.

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM.

Nat Rev Clin Oncol. 2017 Nov;14(11):695-707. doi: 10.1038/nrclinonc.2017.95. Epub 2017 Jul 4. Review.

PMID:
28675164
45.

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL.

Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092.

46.

Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH.

Nat Rev Neurol. 2017 Jun;13(6):363-374. doi: 10.1038/nrneurol.2017.64. Epub 2017 May 12. Review.

PMID:
28497804
47.

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA.

Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.

48.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

49.

Angiogenesis inhibitors in tackling recurrent glioblastoma.

Hundsberger T, Reardon DA, Wen PY.

Expert Rev Anticancer Ther. 2017 Jun;17(6):507-515. doi: 10.1080/14737140.2017.1322903. Epub 2017 May 2. Review.

PMID:
28438066
50.

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.

Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.

Supplemental Content

Loading ...
Support Center